These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 30817899)

  • 1. Misconceptions and Facts About Beta-Blockers.
    Argulian E; Bangalore S; Messerli FH
    Am J Med; 2019 Jul; 132(7):816-819. PubMed ID: 30817899
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Evolution of β-Blockers in Coronary Artery Disease and Heart Failure (Part 1/5).
    Joseph P; Swedberg K; Leong DP; Yusuf S
    J Am Coll Cardiol; 2019 Aug; 74(5):672-682. PubMed ID: 31370960
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cardioprotection with beta-blockers: myths, facts and Pascal's wager.
    Messerli FH; Bangalore S; Yao SS; Steinberg JS
    J Intern Med; 2009 Sep; 266(3):232-41. PubMed ID: 19702791
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of β-blockers in the management of hypertension: an Asian perspective.
    Tomlinson B; Dalal JJ; Huang J; Low LP; Park CG; Rahman AR; Reyes EB; Soenarta AA; Heagerty A; Follath F
    Curr Med Res Opin; 2011 May; 27(5):1021-33. PubMed ID: 21410302
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Beta-blockers can be heart health lifesavers. These drugs can help restore normal heart function in patients with heart failure or who have suffered a heart attack, but they are not for everyone.
    Heart Advis; 2008 Apr; 11(4):7. PubMed ID: 18697234
    [No Abstract]   [Full Text] [Related]  

  • 6. Relation of beta-blocker-induced heart rate lowering and cardioprotection in hypertension.
    Bangalore S; Sawhney S; Messerli FH
    J Am Coll Cardiol; 2008 Oct; 52(18):1482-9. PubMed ID: 19017516
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacology of carvedilol: rationale for use in hypertension, coronary artery disease, and congestive heart failure.
    Ruffolo RR; Feuerstein GZ
    Cardiovasc Drugs Ther; 1997 May; 11 Suppl 1():247-56. PubMed ID: 9211017
    [TBL] [Abstract][Full Text] [Related]  

  • 8. β-Blockers in myocardial infarction and coronary artery disease with a preserved ejection fraction: recommendations, mechanisms, and concerns.
    Nambiar L; Meyer M
    Coron Artery Dis; 2018 May; 29(3):262-270. PubMed ID: 29432284
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antihypertensive and cardioprotective effects of three generations of beta-adrenergic blockers: an historical perspective.
    Chrysant SG; Chrysant GS
    Hosp Pract (1995); 2022 Aug; 50(3):196-202. PubMed ID: 35157531
    [TBL] [Abstract][Full Text] [Related]  

  • 10. How useful are beta-blockers in cardiovascular disease?
    Bangalore S; Parkar S; Messerli FH
    Anadolu Kardiyol Derg; 2006 Dec; 6(4):358-63. PubMed ID: 17162285
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Role of Beta-Blockers in the Treatment of Hypertension.
    Cruickshank JM
    Adv Exp Med Biol; 2017; 956():149-166. PubMed ID: 27957711
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cardiovascular protection using beta-blockers: a critical review of the evidence.
    Bangalore S; Messerli FH; Kostis JB; Pepine CJ
    J Am Coll Cardiol; 2007 Aug; 50(7):563-72. PubMed ID: 17692739
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Beta-adrenergic blockers in heart failure: review of mechanisms of action and clinical outcomes.
    Satwani S; Dec GW; Narula J
    J Cardiovasc Pharmacol Ther; 2004 Dec; 9(4):243-55. PubMed ID: 15678243
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Are we misunderstanding beta-blockers.
    Cruickshank JM
    Int J Cardiol; 2007 Aug; 120(1):10-27. PubMed ID: 17433471
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The safety and tolerability of beta blockers in heart failure with reduced ejection fraction: is the current underutilization of this evidence-based therapy justified?
    Kiel RG; Deedwania P
    Expert Opin Drug Saf; 2015; 14(12):1855-63. PubMed ID: 26488593
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Why beta-blockers should not be used as first choice in uncomplicated hypertension.
    De Caterina AR; Leone AM
    Am J Cardiol; 2010 May; 105(10):1433-8. PubMed ID: 20451690
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nebivolol: a third-generation beta-blocker for hypertension.
    Cheng JW
    Clin Ther; 2009 Mar; 31(3):447-62. PubMed ID: 19393838
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of multiple-action agents on the heart: pathophysiological and therapeutic considerations.
    Magnani B; Rapezzi C; Galié N; Ortolani P
    J Cardiovasc Pharmacol; 1992; 19 Suppl 1():S44-9. PubMed ID: 1378149
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Alpha beta-blockers for patients with hypertension].
    Mizuta Y; Imaizumi T
    Nihon Rinsho; 2006 Aug; 64 Suppl 6():305-9. PubMed ID: 16981560
    [No Abstract]   [Full Text] [Related]  

  • 20. Anthracycline-associated cardiotoxicity in adults: systematic review on the cardioprotective role of beta-blockers.
    Barbosa RR; Bourguignon TB; Torres LD; Arruda LS; Jacques TM; Serpa RG; Calil OA; Barbosa LFM
    Rev Assoc Med Bras (1992); 2018 Aug; 64(8):745-754. PubMed ID: 30673046
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.